Across 88 CTIS-authorized European gastric, gastroesophageal junction (GEJ), and esophageal oncology Phase II/III trial records from 2024–2026, CRO or specialist vendor support appeared in 34 trials, equal to 38.6%. IQVIA and PPD / Thermo Fisher were the most frequent named providers, each appearing in 12 trials, followed by Almac and ICON with 9 trial appearances each. CRO use was concentrated in multi-country EU submissions: 29 of 42 trials with at least 2 countries used CRO support, compared with 5 of 46 single-country trials.
The leading named providers were IQVIA and PPD / Thermo Fisher, each appearing in 12 of 88 trials, equal to 13.6% of all analyzed trials. Almac and ICON followed with 9 trial appearances each, while Medidata and Parexel each appeared in 8 trials. Counts are trial-level appearances; one trial may list more than one CRO or specialist provider.
The CRO landscape is not dominated by one provider. Full-service CROs, central laboratory groups, imaging vendors, eClinical platforms, and trial-supply vendors are all present, indicating that gastric and esophageal oncology outsourcing is usually modular rather than a single-vendor handoff.
CRO use rose sharply once trials moved beyond one-country authorization. Only 5 of 46 single-country trials used CRO support, equal to 10.9%, while 29 of 42 trials with 2 or more countries used CRO support, equal to 69.0%. The highest observed country-footprint band was 4–6 countries, where 10 of 14 trials used CROs, equal to 71.4%.
The strongest outsourcing trigger is not simply trial phase; it is CTIS Part II and EU country coordination. Once a study requires multiple national submissions, localized documents, site activation, monitoring, and vendor coordination, CRO use becomes the majority pattern.
By site count, CRO use was highest in the 31+ site band, where 11 of 19 trials used CRO support, equal to 57.9%. By participant count, CRO use was most common in mid-sized development programs: 14 of 28 trials with 101–250 participants used CROs, equal to 50.0%, and 6 of 13 trials with 251–500 participants used CROs, equal to 46.2%.
CROs are most operationally relevant when a trial becomes multi-country and site-dense, rather than merely high-enrollment. Several very large participant-count trials were single-country or academic-led, which explains why the 501+ participant band did not show CRO use in this dataset.
CRO use was strongest in commercially complex oncology subsets. Gastric/GEJ/esophageal adenocarcinoma trials used CROs in 20 of 40 records, equal to 50.0%, and HER2-positive gastric/GEJ/esophageal trials used CROs in 5 of 10 records, also 50.0%. ADC-containing regimens had the clearest modality signal, with CRO support in 16 of 22 trials, equal to 72.7%.
The highest CRO demand aligns with biomarker-selected, combination, and ADC-heavy development. These trials typically require more vendor layers: central HER2/PD-L1 or ctDNA testing, imaging workflows, eCOA/ePRO systems, safety operations, and trial-supply coordination across EU submissions.
Among the 34 CRO-supported trials, central laboratory, pathology, and biomarker testing were the most common outsourced function, appearing in 27 trials, equal to 79.4%. eCOA/ePRO/EDC/data systems/IRT appeared in 21 trials, equal to 61.8%, while clinical operations, monitoring, or project management appeared in 17 trials, equal to 50.0%.
The dominant outsourcing need is evidence infrastructure rather than simple patient enrollment. Central lab, biomarker, eClinical, and imaging functions appear more often than recruitment support, reflecting the biomarker-rich and endpoint-heavy nature of gastric and esophageal oncology trials.
Yes. Pharma or industry-sponsored trials used CRO support in 32 of 50 trials, equal to 64.0%. Academic, hospital, or non-profit sponsors used CRO support in only 1 of 37 trials, equal to 2.7%.
CRO demand in this market is primarily sponsor-driven. Commercial sponsors appear to outsource trial execution and specialist functions much more often, while academic and hospital-led gastric/esophageal trials tend to remain internally coordinated or institution-network based.
Spain had the highest trial-country participation count, appearing in 38 trial-country records, with CRO support in 27 of them, equal to 71.1%. France, Germany, and Italy followed with 34, 32, and 30 trial-country participations respectively. The most frequent site was Hospital Universitari Vall d’Hebron in Spain, appearing in 28 trial site records, including 19 CRO-supported trial records.
| Country | Trial-country records | CRO-supported | CRO rate |
|---|---|---|---|
| Spain | 38 | 27 | 71.1% |
| France | 34 | 20 | 58.8% |
| Germany | 32 | 18 | 56.3% |
| Italy | 30 | 19 | 63.3% |
| Netherlands | 21 | 6 | 28.6% |
| Belgium | 17 | 11 | 64.7% |
Spain, France, Germany, Italy, and Belgium form the main operational geography for CRO-supported gastric and esophageal oncology trials in Europe. These countries are likely priority targets for CRO feasibility, CTIS Part II readiness, site activation, and country-level submission support.
Several commercial and operational questions can be answered numerically from the same dataset. The strongest adjacent signals are sponsor type, modality complexity, yearly outsourcing direction, and site concentration.
For CRO business development, the best-fit targeting lens is not simply “gastric cancer.” The sharper segment is pharma-sponsored, multi-country, ADC or biomarker-heavy gastric/GEJ/esophageal trials planning CTIS submission across Spain, France, Germany, Italy, and Belgium.
CTIS means Clinical Trials Information System, the EU portal used for clinical trial submission and authorization. CRO means contract research organization. GEJ means gastroesophageal junction. ADC means antibody-drug conjugate. eCOA/ePRO refers to electronic clinical outcome assessment and electronic patient-reported outcomes. EDC means electronic data capture, and IRT/IVRS refers to randomization and trial supply management systems.